144 related articles for article (PubMed ID: 38217946)
1. Is routine axillary lymph node dissection needed to tailor systemic treatments for breast cancer patients in the era of molecular oncology? A position paper of the Italian National Association of Breast Surgeons (ANISC).
Rocco N; Ghilli M; Curcio A; Bortul M; Burlizzi S; Cabula C; Cabula R; Ferrari A; Folli S; Fortunato L; Frittelli P; Gentilini O; Grendele S; Grassi MM; Grossi S; Magnoni F; Murgo R; Palli D; Rovera F; Sanguinetti A; Taffurelli M; Tazzioli G; Terribile DA; Caruso F; Galimberti V
Eur J Surg Oncol; 2024 Feb; 50(2):107954. PubMed ID: 38217946
[TBL] [Abstract][Full Text] [Related]
2. How Often Do Sentinel Lymph Node Biopsy Results Affect Adjuvant Therapy Decisions Among Postmenopausal Women with Early-Stage HR
Pilewskie M; Sevilimedu V; Eroglu I; Le T; Wang R; Morrow M; Braunstein LZ
Ann Surg Oncol; 2022 Oct; 29(10):6267-6273. PubMed ID: 35849294
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
[TBL] [Abstract][Full Text] [Related]
4. Trends in axillary treatment for breast cancer patients undergoing sentinel lymph node biopsy as determined by a questionnaire from the Japanese Breast Cancer Society.
Imoto S; Yamauchi C; Komoike Y; Tsugawa K; Yotsumoto D; Wada N; Ueno T; Oba MS; Shien T; Sugae S; Tsuda H; Yoneyama K
Breast Cancer; 2017 May; 24(3):427-432. PubMed ID: 27553957
[TBL] [Abstract][Full Text] [Related]
5. The intraoperative assessment of sentinel nodes - Standards and controversies.
van der Noordaa MEM; Vrancken Peeters MTFD; Rutgers EJT
Breast; 2017 Aug; 34 Suppl 1():S64-S69. PubMed ID: 28673534
[TBL] [Abstract][Full Text] [Related]
6. Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases.
Mamtani A; Patil S; Van Zee KJ; Cody HS; Pilewskie M; Barrio AV; Heerdt AS; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3481-3486. PubMed ID: 27169771
[TBL] [Abstract][Full Text] [Related]
7. Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer with One to Three Positive Sentinel Lymph Nodes.
Kantor O; Weiss A; Burstein HJ; Mittendorf EA; King TA
Ann Surg Oncol; 2022 Nov; 29(12):7674-7682. PubMed ID: 35763229
[TBL] [Abstract][Full Text] [Related]
8. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.
Classe JM; Loaec C; Gimbergues P; Alran S; de Lara CT; Dupre PF; Rouzier R; Faure C; Paillocher N; Chauvet MP; Houvenaeghel G; Gutowski M; De Blay P; Verhaeghe JL; Barranger E; Lefebvre C; Ngo C; Ferron G; Palpacuer C; Campion L
Breast Cancer Res Treat; 2019 Jan; 173(2):343-352. PubMed ID: 30343457
[TBL] [Abstract][Full Text] [Related]
9. Does ultrasound evaluation of the axilla increase the rate of axillary lymph node dissection in early stage clinically node negative breast cancer patients?
Vasigh M; Meshkati Yazd SM; Karoobi M; Hajebi R; Yazdankhah Kenari A
BMC Surg; 2022 Mar; 22(1):80. PubMed ID: 35241059
[TBL] [Abstract][Full Text] [Related]
10. Additional Nodal Disease Prediction in Breast Cancer with Sentinel Lymph Node Metastasis Based on Clinicopathological Features.
Orsaria P; Caredda E; Genova F; Materazzo M; Capuano I; Vanni G; Granai AV; DE Majo A; Portarena I; Sileri P; Petrella G; Palombi L; Buonomo OC
Anticancer Res; 2018 Apr; 38(4):2109-2117. PubMed ID: 29599329
[TBL] [Abstract][Full Text] [Related]
11. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach.
Damin AP; Zancan M; Melo MP; Biazus JV
Breast Cancer Res Treat; 2021 Apr; 186(2):527-534. PubMed ID: 33165710
[TBL] [Abstract][Full Text] [Related]
12. The State of Surgical Axillary Management and Adjuvant Radiotherapy for Early-stage Invasive Breast Cancer in the Modern Era.
Mann JM; Wu X; Christos P; Nagar H
Clin Breast Cancer; 2018 Aug; 18(4):e477-e493. PubMed ID: 29031423
[TBL] [Abstract][Full Text] [Related]
13. To Dissect or Not to Dissect: Can We Predict the Presence of Four or More Axillary Lymph Node Metastases in Postmenopausal Women with Clinically Node-Negative Breast Cancer?
Farley C; Bassett R; Meric-Bernstam F; Bedrosian I; Caudle A; DeSnyder S; Hunt K; Kuerer H; Singh P; Sun S; Tamirisa N; Teshome M; Hwang RF
Ann Surg Oncol; 2023 Dec; 30(13):8327-8334. PubMed ID: 37670121
[TBL] [Abstract][Full Text] [Related]
14. Axillary ultrasound after neoadjuvant therapy reduces the false-negative rate of sentinel lymph node biopsy in patients with cytologically node-positive breast cancer.
Liu Y; Wang Y; Feng S; Xu Z; Yao M; Huang X; Li P; Wu L; Liu C; Chen X; Liang C; Liu Z
Breast Cancer Res Treat; 2023 Feb; 197(3):515-523. PubMed ID: 36513955
[TBL] [Abstract][Full Text] [Related]
15. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
Boughey JC; Suman VJ; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Kuerer HM; Bowling M; Flippo-Morton TS; Byrd DR; Ollila DW; Julian TB; McLaughlin SA; McCall L; Symmans WF; Le-Petross HT; Haffty BG; Buchholz TA; Nelson H; Hunt KK;
JAMA; 2013 Oct; 310(14):1455-61. PubMed ID: 24101169
[TBL] [Abstract][Full Text] [Related]
16. Nonsentinel Axillary Lymph Node Status in Clinically Node-Negative Early Breast Cancer After Primary Systemic Therapy and Positive Sentinel Lymph Node: A Predictive Model Proposal.
Cebrecos I; Mension E; Alonso I; Castillo H; Sanfeliu E; Vidal-Sicart S; Ganau S; Vidal M; Schettini F
Ann Surg Oncol; 2023 Aug; 30(8):4657-4668. PubMed ID: 36809608
[TBL] [Abstract][Full Text] [Related]
17. Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy-A Rare Event.
Barrio AV; Montagna G; Mamtani A; Sevilimedu V; Edelweiss M; Capko D; Cody HS; El-Tamer M; Gemignani ML; Heerdt A; Kirstein L; Moo TA; Pilewskie M; Plitas G; Sacchini V; Sclafani L; Tadros A; Van Zee KJ; Morrow M
JAMA Oncol; 2021 Dec; 7(12):1851-1855. PubMed ID: 34617979
[TBL] [Abstract][Full Text] [Related]
18. Comparing Early-Stage Breast Cancer Patients with Sentinel Lymph Node Metastasis with and without Completion Axillary Lymph Node Dissection: A Systematic Review and Meta-Analysis.
Heiranizadeh N; Rafiei Shahamabadi M; Dehghan HR; Jafari-Nedooshan J; Kargar S; Zare M; Amooei A; Shiryazdi SM; Broomand MA; Moravej MT; Sadri Z
Asian Pac J Cancer Prev; 2022 Aug; 23(8):2561-2571. PubMed ID: 36037108
[TBL] [Abstract][Full Text] [Related]
19. Conservative axillary surgery is emerging in the surgical management of breast cancer.
Noguchi M; Inokuchi M; Yokoi-Noguchi M; Morioka E; Haba Y
Breast Cancer; 2023 Jan; 30(1):14-22. PubMed ID: 36342647
[TBL] [Abstract][Full Text] [Related]
20. Management of the axilla in postmenopausal patients with cN0 hormone receptor-positive/HER2-negative breast cancer treated with neoadjuvant endocrine therapy and its prognostic impact.
Garcia-Tejedor A; Falo C; Fernandez-Gonzalez S; Laplana M; Gil-Gil M; Soler-Monso T; Martinez-Perez E; Calvo I; Calpelo H; Bajen MT; Benitez A; Ortega R; Petit A; Guma A; Campos M; Stradella A; Lopez-Ojeda A; Ponce J; Pla MJ; Pernas S
Breast Cancer Res Treat; 2023 Jun; 199(3):445-456. PubMed ID: 37043108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
